Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 329993 in Paroxysmal Atrial Fibrillation
NCT01710852Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Oct 2012
- Primary completion
- Apr 2014
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of ISIS-329993 in Atrial fibrillation (AFib), sponsored by Ionis Pharmaceuticals. Started Oct 2012; status: completed.
02
Drugs
ISIS-329993
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT01710852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01710852.